Avalyn Pharma Announces Results for Quarter Ended June 30, 2026

What Happened
Avalyn Pharma Inc. (AVLN) announced its financial results for the quarter ended June 30, 2026 by filing a Current Report on Form 8-K on August 12, 2026. The company furnished a press release detailing those results as Exhibit 99.1 to the 8-K. The filing was signed by CEO Lyn Baranowski.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Accession No. 0001193125-26-345807).
• Item reported: 2.02 — Results of Operations and Financial Condition; press release furnished as Exhibit 99.1.
• Filing was signed by Lyn Baranowski, Chief Executive Officer.
• The filing also includes the Cover Page Interactive Data File (Inline XBRL).

Why It Matters
This 8-K notifies investors that Avalyn has released its quarterly results; those results (revenue, profit/loss, cash position, and any management commentary) can affect the stock and investor decisions. Retail investors should read the furnished press release and the company’s subsequent periodic filings (e.g., 10-Q) for the full financial details and any guidance.